Shanghai Affinity Biopharmaceutical

Affinity Biopharmaceutical is a clinical-stage biotechnology company dedicated to the development of innovative precision oncology drugs. The company leverages its proprietary IDEAL (Immune-Directed Effector-Activated Ligand) platform to engineer masked therapeutic agents that remain inactive in systemic circulation. These molecules are specifically designed to be activated by proteases, such as Fibroblast Activation Protein (FAP), which are highly expressed within the tumor microenvironment. This localized activation strategy allows for the delivery of potent payloads, including cytokines and immune agonists, while minimizing off-target systemic toxicities. Affinity's lead clinical programs, AFN-001 and AFN-002, target IL-15 and IL-2 pathways respectively, aiming to provide safer and more effective treatment options for patients with advanced solid tumors. The company is headquartered in Shanghai with additional research and manufacturing facilities in Suzhou.